Cancer Chemotherapy and Pharmacology

, Volume 68, Issue 1, pp 225–226

Sandostatin desensitization–a strategy useful for patients with carcinoid tumors, intolerant to sandostatin

Original Article

DOI: 10.1007/s00280-010-1436-4

Cite this article as:
Vinjamaram, S. & Iyer, R. Cancer Chemother Pharmacol (2011) 68: 225. doi:10.1007/s00280-010-1436-4


Sandostatin immediate release (IR) is frequently used to treat patients with carcinoid tumors. However, some patients are unable to tolerate the immediate side effects of sandostatin IR leading to discontinuation of the drug. There is no literature available to guide the management of patients’ sensitivity/intolerance to sandostatin IR. We report a 49-year-old male with carcinoid tumor who was intolerant to sandostatin IR initially but was able to tolerate the drug after we employed a desensitization strategy.


Carcinoid Sandostatin Long-acting sandostatin Depot preparation 

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Department of OncologyInnovis HealthFargoUSA
  2. 2.Department of MedicineRoswell Park Cancer InstituteBuffaloUSA

Personalised recommendations